

**Lundquist Institute for Biomedical Innovation
at Harbor-UCLA Medical Center**

Institutional Biosafety Committee

Meeting Minutes

03/10/2026

MRL 419 and Zoom Virtual Conference

MEMBERS PRESENT

Jonathan Abdala, B.S.
David Applebaum, M.S.
Begona Diaz, Ph.D.
Rami Doueiri, Ph.D.
Scott Filler, M.D.
Catalina Guerra, DVM
Adrienne Zweifel, Ph.D.

MEMBERS ABSENT

Helen Chun, Ph.D. (left early due to technical
issues with Zoom)
Fang Wang, Ph.D.

STAFF PRESENT

Elizabeth Burrola, CIP
Rosa Harmon, CPIA
Annie Hilo (left early due to technical issues with
Zoom)

STAFF ABSENT

Rosemary Madnick, MBA

1. CALL TO ORDER

The meeting was called to order by Scott Filler, M.D. at 3:03 PM.

2. MEETING MINUTES

The minutes of the February 10, 2026 meeting were presented.

A motion was made and seconded to APPROVE the minutes.

Vote: For - 7, Opposed - 0, Absent – 0, Abstained - 0, Recused – 0

3. BUA REVIEW

A. Initial Reviews

IBC #: IBC 2026-U-Lenti EY

PI: Eiji Yoshihara, Ph.D.

iRIS Ref #: 063720

Summary: This Umbrella BUA involves the in vitro packaging of a 3rd generation replication-incompetent lentiviral vector and its subsequent use in the transduction of human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPS). The lentiviral vectors are used to introduce PD-L1 overexpression constructs prior to differentiation into HILO cells (Human iPSC-derived islet-like organoids). Lab strains of *E. coli* will be used to propagate the lentiviral plasmids and the genetically modified human established cell lines will be administered to mice.

Inserts: CD274 (PD-L1)

Vectors: Lentivirus (3rd generation), pLV-human PDL1(CD274)-GIII-EF1a, pRSV-Rev (3rd), pMDLg/pRRE (3rd), pCMV-VSV-G (3rd)

Pathogens: NA

Risk Assessment: Risk Group 1, Risk Group 2

Containment: BSL-1, BSL-2; ABSL2

Training: Training has been verified by the Research Compliance Office Staff and EHS.

NIH Guidelines: III-D for Lentivirus, III-E for *E. coli*.

Conflicts: NA

Motion: A motion was made and seconded to REQUIRE MODIFICATIONS TO SECURE APPROVAL of the BUA.

Modifications Required to BUA:

1. Section 5.0 – Project Overview

The PI is to define “HILO” cells at first use.

2. Section 6.0 - NIH Guidelines/IBC Review Exemptions

For item 6.6, the PI is to select the appropriate checkbox under Section III-E for *E. coli*.

3. Section 10.0 - DNA Plasmids

For each entry, the PI is to check the "Eukaryotic Hosts" box to indicate that plasmids will be added to the eukaryotic hosts (HEK293 for packaging purposes).

4. Section 16.0 - Experimental Procedures and Emergency Response

Experimental Procedures (16.1) - referencing "Standard Procedures" or "Institutional Biosafety Guidelines" or "Aerosol-generating procedures, if applicable, will be conducted under appropriate containment conditions." is not a sufficient description. The PI is to provide details on what aerosol-generating procedures are expected to be performed and how the risk of aerosol exposure will be mitigated.

- a. The PI is to add more detail on how the *E. coli* will be cultured and handled
- b. The PI is to replace the phrase "or other approved transplantation methods." with other possible inoculation routes or remove this text completely if only subcutaneous route of administration will be performed.
- c. The PI is to indicate what materials will be harvested from the mice.
- d. For Biological Safety Cabinets (16.2), the PI is to de-select the “Hard-ducted” box and select the “recirculating” box instead.

Vote: For - 7, Opposed - 0, Absent - 0, Abstained – 0, Recused – 0

4. **OTHER BUSINESS**

A. Safety Committee Report – Accidents/Spills

Mr. Applebaum stated no incidents were reported.

B. Incident Reporting Form

The members reviewed a revised version of the incident reporting form which will be available in iRIS for investigators to complete when required. The members recommended further revising the form to allow investigators to respond to individual questions, as applicable, rather than providing a narrative. Also, a field for IRB protocol information will be added.

C. Reportable Incident:

The members were informed that an incident report to the Office of Science and Technology Policy will be submitted regarding an investigator's conduct of experiments that required IBC approval before commencing the experiments.

The IBC FAQs will be revised to include instructions for investigators on how to submit an incident report and will be distributed to TLI investigators every six months.

c. TLI IBC Procedures document draft

Tabled for the next meeting due to time constraints.

d. Self-Assessment Tool: Physical Containment – Laboratory Environment section

Tabled for the next meeting due to time constraints.

With no further business, the meeting adjourned at 3:58 AM

Respectfully submitted,

Signed by:



19F1076B3027451...

Scott Filler, M.D.

Chair, Institutional Biosafety Committee

cc: Research Committee Agenda